The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma

Erkisi M., Erkurt E., Ozbarlas S., Burgut R., Doran F., Seyrek E.

JOURNAL OF CHEMOTHERAPY, vol.8, no.3, pp.224-228, 1996 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 8 Issue: 3
  • Publication Date: 1996
  • Doi Number: 10.1179/joc.1996.8.3.224
  • Title of Journal : JOURNAL OF CHEMOTHERAPY
  • Page Numbers: pp.224-228


Sixty patients with stage III-B and IV soft tissue sarcomas were randomized to receive either ifosfamide 5g/m(2)xdx1 and doxorubicin 60mg/m(2)xdx1 given every 3 weeks (arm A) or ifosfamide 1.8g/m(2)xdx5 and doxorubicin 60mg/m(2)xdx1 given every 4 weeks (arm B). Recombinant human granulocyte colony-stimulating factor (r-met Hu G-CSF: 250 mu g/m(2)xd) was applied with a prophylactic intent to patients in arm A only. The response rate was higher in arm A patients (56% versus 33%, p=0.03). In stage III patients, the complete response rate was significantly higher (53% versus, 13.3%, p=0.01) and the duration of response was significantly longer in arm A (20+/-8.2 months versus, 13.4+/-7 months, p=0.05). Chemotherapy related myelotoxicity and mucositis were also less frequent in this arm as a result of propylactic r-met Hu G-CSF administration (p=0.04, p=0.003).